Study Title

telixpharmaceuticals

A Single Arm, Phase 2 Trial of External Beam Radiation Therapy (EBRT) in Combination With 177Lu-DOTA-TLX591-CHO in Patients With Biochemically Recurrent Oligometastatic, Prostate Specific Membrane Antigen-Expressing Prostate Cancer

Study Details

Description:

This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer. TLX591 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radiosotope for the treatment of PSMA-expressing tumours.

Sponsor:

Telix Pharmaceuticals

Contacts:

Julie Gisbon

julie.gibson@telixpharma.com

317-588-9700

Charlotte Hawkins, PhD

charlotte.hawkins@telixpharma.com

317-588-9700

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Not yet provided. Contact Julie Gisbon for more information.

317-588-9700

julie.gibson@telixpharma.com